Market Overview

UPDATE: Piper Jaffray Lowers PT on AngioDynamics on Lowered Revenues, Earnings Estimates

Related ANGO
Mid-Afternoon Market Update: AngioDynamics Drops On Earnings Miss; Zynerba Pharmaceuticals Shares Spike Higher
18 Biggest Mid-Day Losers For Thursday

In a report published Friday, Piper Jaffray reiterated its Neutral rating on AngioDynamics (NASDAQ: ANGO), but slightly lowered its price target from $12.00 to $11.00.

Piper Jaffray noted, “We are keeping our Neutral rating on ANGO after the pre-released Q3 (Feb). Revenues were unexpectedly low, with a myriad of contributors to the miss. Earnings will also miss with negative leverage. Our Neutral rating reflects a mid-point between our new slower growth assumptions and uncertainty in the timing of a turnaround, and the counterbalancing of the lower valuation that investors have quickly placed on ANGO shares. We are lowering our PT from $12 to $11 to reflect the slower growth, lower numbers, and uncertain timing.”

AngioDynamics closed on Thursday at $11.00.

Latest Ratings for ANGO

Jul 2017BarclaysMaintainsEqual-Weight
Feb 2017BarclaysInitiates Coverage OnEqual-Weight
Nov 2016Cantor FitzgeraldInitiates Coverage OnBuy

View More Analyst Ratings for ANGO
View the Latest Analyst Ratings

Posted-In: Piper JaffrayAnalyst Color Price Target Analyst Ratings


Related Articles (ANGO)

View Comments and Join the Discussion!

Partner Center